Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors.

MLA

John, Jessy, et al. “Divergent Outcomes of Anti-PD-L1 Treatment Coupled with Host-Intrinsic Differences in TCR Repertoire and Distinct T Cell Activation States in Responding versus Non-Responding Tumors.” Frontiers in Immunology, vol. 13, Oct. 2022, p. 992630. EBSCOhost, https://doi.org/10.3389/fimmu.2022.992630.

APA

John, J., Woolaver, R. A., Popolizio, V., Chen, S. M. Y., Ge, H., Krinsky, A. L., Vashisht, M., Kramer, Y., Chen, Z., & Wang, J. H. (2022). Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors. Frontiers in Immunology, 13, 992630. https://doi.org/10.3389/fimmu.2022.992630

Chicago

John, Jessy, Rachel A Woolaver, Vince Popolizio, Samantha M Y Chen, Huaibin Ge, Alexandra L Krinsky, Monika Vashisht, Yonatan Kramer, Zhangguo Chen, and Jing H Wang. 2022. “Divergent Outcomes of Anti-PD-L1 Treatment Coupled with Host-Intrinsic Differences in TCR Repertoire and Distinct T Cell Activation States in Responding versus Non-Responding Tumors.” Frontiers in Immunology 13 (October): 992630. doi:10.3389/fimmu.2022.992630.